Champions Oncology Reports Record Quarterly Revenue of $14.0 Million

Rhea-AI Summary

Champions Oncology (NASDAQ:CSBR) reported its Q1 FY2026 financial results with revenue of $14.0 million, slightly down from $14.1 million in the same period last year. The quarter was marked by the appointment of Rob Brainin as the new CEO and delivered an Adjusted EBITDA of $60,000.

The company experienced a 3% decline in service revenue but saw an increase in data license revenue. Operating expenses rose to $14.5 million, up 14.1% year-over-year, resulting in an operating loss of $527,000. Gross margin decreased to 43% from 50% in the prior year. The company maintains a strong financial position with $10.3 million in cash and no debt.

Positive

• Strong cash position of $10.3 million with no debt
• Positive operating cash flow of $600,000 for the quarter
• Data license revenue showed growth with increased demand
• Strategic migration of lab services in-house expected to improve future margins

Negative

• Revenue declined slightly year-over-year to $14.0 million from $14.1 million
• Operating loss of $527,000 compared to $1.3 million income in prior year
• Adjusted EBITDA decreased to $59,000 from $2.0 million year-over-year
• Gross margin declined to 43% from 50% in prior year
• Operating expenses increased 14.1% to $14.5 million

Insights

Financial Analyst

Champions reports steady $14M revenue but declining profitability with new CEO focused on dual growth strategy.

Champions Oncology delivered $14 million in revenue for Q1 FY2026, representing flat performance year-over-year but sequential growth from the previous quarter. The most concerning metric is the significant decline in profitability – adjusted EBITDA plummeted from $2 million in Q1 FY2025 to just $60,000 this quarter, while the company swung from $1.3 million operating income to a $527,000 operating loss.

The deterioration in financial performance stems from multiple factors. Gross margin contracted from 50% to 43% due to increased reliance on costly outsourced lab services for radiolabeling work. Management noted this is temporary as they plan to migrate this work in-house. Additionally, R&D expenses surged by 43.2% to $2.1 million, reflecting investments in their data licensing platform. Sales and marketing costs also increased by 10.5% to support data license business growth.

Despite these profitability challenges, there are positive indicators. The company generated approximately $600,000 in operating cash flow during the quarter and maintains a solid balance sheet with $10.3 million cash and no debt. The newly appointed CEO Rob Brainin has outlined a two-pronged growth strategy focusing on strengthening the core services business while scaling their emerging data platform.

This quarter appears to be one of strategic investment rather than immediate financial returns. Management is clearly prioritizing building capabilities that could drive long-term growth over short-term profits. Investors should monitor whether these investments translate to revenue acceleration and margin recovery in coming quarters, particularly as the company brings more lab work in-house and scales its data licensing business.

Positive start to FY 2026 with steady revenue, data growth and new leadership

HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2026, ended July 31, 2025.

First Quarter and Recent Highlights:

• Total revenue of $14 million

• Adjusted EBITDA of $60,000

• Appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth

Rob Brainin, newly appointed CEO of Champions, commented, "It is great to be joining Champions at such an exciting inflection point. Our core services business - the backbone of our company - is strengthening and well positioned for sustained growth. At the same time, we are scaling our emerging data platform, which has already shown encouraging traction with leading biopharma partners. These complementary growth engines give us the opportunity to deepen our scientific impact, deliver innovative solutions to patients and customers, and create durable long-term value for shareholders. In parallel, our Corellia team continues to generate data demonstrating the potential of the compounds in our pipeline. Over the coming quarters, I look forward to working closely with our talented team to sharpen our strategy, invest in key capabilities, and build on Champions' culture of collaboration and scientific excellence."

David Miller, CFO of Champions, added, "We opened the fiscal year with $14 million in revenue and adjusted EBITDA of $60,000. While revenue was slightly lower than the first quarter of last year, we achieved solid sequential growth that met our expectations and provides a strong foundation for the year. As we move forward, we anticipate continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for our proprietary data offerings. Our financial discipline and focus on profitable growth give us the flexibility to invest in strategic initiatives that will position Champions for long-term success."

First Fiscal Quarter Financial Results

Total oncology revenue for the first quarter of fiscal 2026 was $14.0 million compared to $14.1 million for the same period last year, consisting of a $400,000, or 3% decline in service revenue and a $300,000 increase in data license revenue. Total costs and operating expenses for the first quarter of fiscal 2026 were $14.5 million compared to $12.7 million for the first quarter of fiscal 2025, an increase of $1.8 million or 14.1%.

For the first quarter of fiscal 2026, Champions reported a loss from operations of $527,000, including $208,000 in stock-based compensation, $358,000 in depreciation and amortization expenses, and a $20,000 charge for the disposal of lab equipment, compared to income from operations of $1.3 million, inclusive of $258,000 in stock-based compensation and $448,500 in depreciation and amortization expenses, in the first quarter of fiscal 2025. Adjusted EBITDA, which is defined as income from operations excluding stock-based compensation, depreciation and amortization expenses, and equipment disposal charges, was $59,000 for the first quarter of fiscal 2026 compared to adjusted EBITDA of $2.0 million in the first quarter of fiscal 2025.

Cost of oncology revenue was $8.0 million, up $923,000, or 13.1%, from $7.1 million in the same period last year. The increase primarily reflects higher outsourced lab services for radiolabeling work, which will vary from quarter to quarter. Importantly, as we migrate this work into our own labs in the coming quarters, we anticipate a reduction in cost of sales and improvement in gross margins. Gross margin for the quarter was 43% compared to 50% in the prior year.

Research and development expense for the three-months ended July 31, 2025 was $2.1 million, an increase of $628,000 or 43.2%, compared to $1.5 million for the three-months ended July 31, 2024. The increase reflected greater investment in sequencing and related costs to develop our data licensing platform. Sales and marketing expense for the three-months ended July 31, 2025 was $1.9 million, an increase of $176,000, or 10.5%, compared to $1.7 million for the three-months ended July 31, 2024. The increase was related to compensation expense to support the growth of our data license business. General and administrative expense for the three-months ended July 31, 2025 was $2.6 million, an increase of $43,000, or 1.7%, compared to $2.5 million for the three-months ended July 31, 2024 driven primarily from an increase in IT related costs.

Net cash provided by operating activities was approximately $600,000 for the quarter, supported by receivables conversion and normal working capital activity, partially offset by a quarterly net loss. Net cash used in investing activities for the three-months ended July 31, 2025 was approximately $46,000 for lab and computer equipment. Net cash used in financing activities for the three-months ended July 31, 2025 was $14,000 resulting from financing lease payments slightly offset by proceeds from options exercises.

The Company ended the quarter with cash on hand of approximately 10.3 million and no debt, providing us with a strong balance sheet and financial flexibility.

Conference Call Information:

The Company will host a conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its first quarter financial results. To participate in the call, please call 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 261008, or provide the verbal reference "Champions Oncology".

Full details of the Company's financial results will be available by or before on September 15, 2025 in the Company's Form 10-Q at www.championsoncology.com.

* Non-GAAP Financial Information

This press release contains "Non-GAAP financial measures," which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP").

A further explanation and reconciliation of these Non-GAAP financial measures is included below and in the financial tables in this release.

The Company believes that the Non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company's management uses Non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results and for internal planning and forecasting purposes. Adjusted EBITDA and Adjusted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or EPS as indicators of our operating performance or to net cash provided by operating activities as a measure of our liquidity. We believe the Company's Adjusted EBITDA and Adjusted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate Non-GAAP financial results differently, particularly related to nonrecurring, unusual items.

Adjusted EBITDA

Adjusted EBITDA represents net income (loss), or net income (loss) from operations, excluding the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.

Adjusted Net Income (Loss) and Adjusted Earnings Per Share (EPS)

Adjusted net income (loss) (if denoted) and adjusted EPS exclude the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.

About Champions Oncology, Inc.

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

Media Inquiries:

Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/

This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2025 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.

Champions Oncology, Inc.
(Dollars in thousands)

Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA - (Non-GAAP) (Unaudited)

		Three Months Ended July 31,
		2025				2024
Net (loss) income - GAAP		$	(466	)		$	1,313
Less:
Stock-based compensation			208				258
Depreciation and amortization			358				448.5
Loss on equipment disposal		$	20			$	-
Adjusted EBITDA - Non-GAAP		$	120			$	2,020

Reconciliation of GAAP EPS to Non-GAAP EPS (Unaudited)

		Three Months Ended July 31,
		2025				2024
EPS - basic, GAAP		$	(0.03	)		$	0.10
Less:
Effect of stock-based compensation on EPS			0.02				0.02
Effect of depreciation and amortization on EPS			0.03				0.03
Effect of loss on equipment disposal on EPS			0.001				-
Adjusted EPS - basic, Non-GAAP		$	0.02			$	0.15

		Three Months Ended July 31,
		2025				2024
EPS - diluted, GAAP		$	(0.03	)		$	0.09
Less:
Effect of stock-based compensation on EPS			0.02				0.02
Effect of depreciation and amortization on EPS			0.03				0.03
Effect of loss on equipment disposal on EPS			0.001				-
Adjusted EPS - diluted, Non-GAAP		$	0.02			$	0.14

Unaudited Condensed Consolidated Statements of Operations (unaudited)

		Three Months Ended July 31,
		2025				2024
Oncology revenue		$	13,995			$	14,061
Cost of oncology revenue			7,995				7,072
Research and development			2,082				1,454
Sales and marketing			1,855				1,679
General and administrative			2,570				2,527
Loss on disposal of equipment			20				-
(Loss) income from operations			(527	)			1,329
Other income, net			75				5
(Loss) income before provision for income taxes			(452	)			1,334
Provision for income taxes			14				21
Net (loss) income		$	(466	)		$	1,313
Less: net loss attributable to noncontrolling interest			30				-
Net (loss) income attributable to Company's common shares		$	(436	)		$	1,313
Net (loss) income per common share outstanding
basic		$	(0.03	)		$	0.10
and diluted		$	(0.03	)		$	0.09
Weighted average common shares outstanding
basic			13,788,414				13,593,766
and diluted			13,788,414				14,042,379

Condensed Consolidated Balance Sheets

		July 31, 2025				April 30, 2025
		(unaudited)
Cash and cash equivalents		$	10,325			$	9,785
Accounts receivable, net			9,474				11,204
Other current assets			1,215				1,369
Total current assets			21,014				22,358
Operating lease right-of-use assets, net			4,771				5,080
Property and equipment, net			4,230				4,375
Other long term assets			196				196
Goodwill			335				335
Total assets		$	30,546			$	32,344
Accounts payable and accrued liabilities		$	6,646			$	6,804
Current portion of operating lease liabilities			1,506				1,471
Other current liabilities			116				135
Deferred revenue			14,430				15,443
Total current liabilities			22,698				23,853
Non-current operating lease liabilities			4,244				4,634
Other Non-current Liability			66				85
Total liabilities			27,008				28,572
Total stockholders' equity attributable to Champions Oncology, Inc.			3,508				3,772
Noncontrolling interest			30				-
Total stockholders' equity			3,538				3,772
Total liabilities and stockholders' equity		$	30,546			$	32,344

Unaudited Condensed Consolidated Statements of Cash Flows (unaudited)

		Three Months Ended July 31,
		2025				2024
Cash flows from operating activities:
Net (loss) income		$	(466	)		$	1,313
Adjustments to reconcile net (loss) income to net cash provided by operations:
Stock-based compensation expense			208				258
Operating lease right-of use assets			310				289
Depreciation and amortization expense			358				449
Loss on disposal of equipment			20				-
Allowance for doubtful accounts and estimated credit losses			(29	)			(71	)
Changes in operating assets and liabilities			199				(1,927	)
Net cash provided by operating activities			600				311
Cash flows from investing activities:
Purchases of property and equipment			(46	)			-
Net cash used in investing activities:			(46	)			-
Cash flows from financing activities:
Proceeds from the exercise of stock options			24				-
Finance lease payments			(38	)			(37	)
Net cash used in financing activities:			(14	)			(37	)
Net increase in cash			540				274
Cash at beginning of period			9,785				2,618
Cash at the end of period		$	10,325			$	2,892

SOURCE: Champions Oncology, Inc.

View the original press release on ACCESS Newswire

FAQ

What were Champions Oncology's (CSBR) Q1 2026 earnings results?

Champions Oncology reported Q1 FY2026 revenue of $14.0 million, slightly down from $14.1 million year-over-year, with an Adjusted EBITDA of $60,000 and an operating loss of $527,000.

Who is the new CEO of Champions Oncology (CSBR)?

Rob Brainin was appointed as the new Chief Executive Officer to lead Champions Oncology's next phase of growth.

What is Champions Oncology's (CSBR) current cash position?

The company ended Q1 FY2026 with $10.3 million in cash and no debt, providing strong financial flexibility.

How did Champions Oncology's (CSBR) operating expenses change in Q1 2026?

Total costs and operating expenses increased by $1.8 million or 14.1% to $14.5 million compared to $12.7 million in Q1 FY2025.

What was Champions Oncology's (CSBR) gross margin in Q1 2026?

The gross margin for Q1 FY2026 was 43%, down from 50% in the prior year, primarily due to higher outsourced lab services costs.